COPD

Panelists discuss how chronic obstructive pulmonary disease (COPD) management follows a stepwise approach, beginning with bronchodilators (typically short-acting β2-agonists/long-acting β2-agonists) and progressing to combination therapy with long-acting muscarinic antagonists/inhaled corticosteroids based on symptom severity. Current unmet needs include more targeted anti-inflammatory treatments, better biomarkers for phenotyping, and therapies to halt disease progression, particularly for those who don’t respond well to conventional treatments.

Panelists discuss how, despite being preventable and treatable, chronic obstructive pulmonary disease (COPD) has emerged as a major global health challenge due to widespread exposure to risk factors, particularly tobacco smoke, which remains the primary cause despite declining smoking rates in some regions. Early environmental exposures play a crucial role—workplace pollutants, air pollution, and secondhand smoke can damage developing lungs, whereas genetic factors like α1-antitrypsin deficiency increase susceptibility.

A study shows the causal link between apoA-I and chronic obstructive pulmonary disease, showing lipid metabolism's role in the pathogenesis of COPD.

The analysis of UnitedHealth Group claims data found the per-patient cost of cirrhosis care exceeded that of HF and COPD by 21.7% and 55.0%, respectively.

Within 2 years of death, fall-risk increasing drug burden was associated with greater odds of an injurious fall.

Lungcast reflects on this year in pulmonology, looking back at such topics ranging from the American Lung Association ‘State of the Air’ report to artificial intelligence in lung imaging.

In this month's episode of Lungcast, Jacob Sands, MD, discusses the American Lung Association’s recently newly-released 2024 State of Lung Cancer report.

This portion of the latest Lungcast episode includes a discussion of therapies, triggers, and management of AERD.

During his interview, Criner discusses several notable updates to the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report regarding COPD care.

This segment of Han’s interview featured a discussion of the safety profile of dupilumab and ensifentrine, as well as other details in the GOLD 2025 Report.

In this interview, Han highlighted new information included in the GOLD 2025 Report regarding utilization of dupilumab and ensifentrine for certain patients with COPD.

In these updates and new sections, the 2025 GOLD report included highlighted climate change, cardiovascular risk, and pulmonary hypertension.

A trio of stakeholders join Lungcast to discuss the ongoing, long-term assessment into the patterns and drivers of chronic lung disease in a real-world cohort.

Antonio Anzueto, MD, discusses how dupilumab fits into treatment algorithms for patients with uncontrolled COPD.

Stephanie Christenson, MD, discusses the impact of recent regulatory approvals and pipeline movement for chronic obstructive pulmonary disease.

New research presented at CHEST 2024 highlights ensifentrine’s effectiveness in improving lung function, symptoms, and quality of life for COPD patients, regardless of disease severity.